Evidence Table 77. KQ2—Continuous data—High-density lipoprotein cholesterol (HDL-C)

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD /**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bays 20106  parallel | Unclear | atorvastatin | 10-40 | Omega-3 (EPA, DHA, or both). | 122 |  | Mean:  Median 39.8  SD: 34  SE:48  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:2.4  Median:  SD:  P:<0.001 |  | medium |
|  | Placebo | 121 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Bays 20106 parallel | Unclear | atorvastatin | 10-40 | Omega-3 (EPA, DHA, or both). | 122 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:6.3  Median:  SD:  P:0.001 |  | medium |
|  | Placebo | 121 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |

| Evidence Table 77. KQ2—Continuous data—High-density lipoprotein cholesterol (HDL-C) (continued) | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD /**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Mabuchi 200739 parallel | Unclear | atorvastatin | 1 | Coenzyme Q10. | 24 |  | Mean: 1.74  Median  SD: 0.42  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P:  0.0033 | Mean:  Median:  SD:  P: | "...no significant differences between the groups" | medium |
|  | Placebo | 25 | Mean:1.61  Median  SD: 0.34  SE:  Lower:  Upper: | Mean:  Median:  SD:  P:  0.0583 |
| Young 200770 parallel | Mod and high risk | simvastatinstatin | 10-40 | Coenzyme Q10. | 22 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P:  0.65 | No difference in groups (p=0.65) | medium |
|  | Placebo | 22 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Davidson 200714 parallel | Unclear | simvastatinstatin | 40 | Omega-3 (EPA, DHA, or both). | 122 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P:  <0.001 |  | medium |
|  | Placebo | 132 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  -1.10  Median:  SD:  P: |
| Meyer 200746 parallel | Unclear | simvastatinstatin | 81 | Fish/marine oils. | 13 |  | Mean: 1.16  Median  SD:  SE:0.09  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Fish/marine oils. 8g/d | 13 | Mean: 1.21  Median  SD:  SE:0.05  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: |
|  | Placebo | 14 | Mean:1.11  Median  SD:  SE:0.10  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Sutken 200663 parallel | Low and/or Moderate | Gemfibrozil | 1200 | Vitamin E. | 22 |  | Mean: 0.82  Median  SD:  SE:0.04  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P:  <0.05 | Mean:  Median:  SD:  P: |  | high |
|  | Placebo | 23 | Mean:0.82  Median  SD:  SE:0.04  Lower:  Upper: | Mean:  Median:  SD:  P:  <0.05 |
| Sutken 200663 parallel | Low and/or Moderate | Gemfibrozil | 1200 | Vitamin E. | 12 |  | Mean: 1.57  Median  SD:  SE:0.04  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P:  <0.01 | Mean:  Median:  SD:  P: |  | high |
|  | Placebo | 10 | Mean:1.41  Median  SD:  SE:0.08  Lower:  Upper: | Mean:  Median:  SD:  P:  <0.01 |
| Macan 200640 parallel | Low and/or Moderate | Warfarin | NR | Garlic. | 22 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:2.9  % mean:  Median:  SD:  7.9  P: | Mean:  Median:  SD:  P:  0.038 | Other continous outcome assessed in this study: hemoglobin (weight also but I stated this in another comment as well) | medium |
|  | Placebo | 26 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:-1.6  Median:  SD:  6.7  P: |
| Manuel 200442  parallel | At high risk for CHD | Atorvastatin | 20 | Vitamin E. | 11 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | Data not presented in paper - only provides baseline data per group and states that this outcome 'did not change in either group'. | medium |
|  | Placebo | 11 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Playford 200358 parallel | At high risk for CHD | Fenofibrate | 200 | Coenzyme Q10.  200 mg plus 200 mg fenofibrate | 18 |  | Mean: 1.07  Median  SD: 0.05  SE:  Lower:  Upper: | Mean:0.14  % mean:  Median:  SD:  P: | Mean:0.04 (group 1 vs. group 2  Median:  SD:  P:0.385  Mean:0.09  (group 1 vs. group 3  Median:  SD:  P:0.001 |  | low-medium |
|  | No treatment (aside from CVD drug) | 17 | Mean:1.11  Median  SD:  SE:0.04  Lower:  Upper: | Mean:0.17  Median:  SD:  P: |
|  | Coenzyme Q10.  200 mg CoQ10 only | 20 | Mean:0.98  Median  SD:  SE:0.04  Lower:  Upper: | Mean:0.03  Median:  SD:  P: |
|  | Placebo | 18 | Mean:0.98  Median  SD:  SE:0.04  Lower:  Upper: | Mean:-0.05  Median:  SD:  P: |
| Svaneborg 200264 parallel | At low risk for CHD (0-1 risk factors) | ASA | 100 | Omega-3 (EPA, DHA, or both). | 12 |  | Mean:  Median 1.18  SD: 0.73  SE:1.38  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | placebo= corn oil containing omega-6 | medium |
|  | Placebo | 6 | Mean:1.05  Median  SD:  SE:  Lower: 0.88  Upper:1.45 | Mean:  Median:  SD:  P: |
| Duffy 200120  parallel | Low and/or Moderate | simvastatinstatin | 10-40 | Vitamin E  1000 IU vitmain E plus simvastatin | 6 |  | Mean: 1.4  Median  SD: 0.4  SE:  Lower:  Upper: | Mean:-0.1  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
| No treatment (aside from CVD drug) | 7 | Mean:1.3  Median  SD: 0.3  SE:  Lower:  Upper: | Mean:0  Median:  SD:  P: |
| 1000IU Vitamin E | 6 |  | Mean:1.4  Median  SD: 0.3  SE:  Lower:  Upper: | Mean:0.1  Median:  SD:  P: |  |  |  |
| Placebo | 7 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean-0.1  Median:  SD:  P: |  |  |  |
| Napoli 199852 parallel | Unclear | Pravastatin | 20-40 | Vitamin E. | 52 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean: 9  Median:  SD:  3%  P:  <0.05 | Mean:  Median:  SD:  P: | Data not extracted but also available for VLDL-C, IDL-C, ApoB, Apo AI, Apo AII. Further, data not reported for routine laboratory tests and adverse effects. For these outcomes it is reported that “no differences in routine laboratory tests and adverse effects were registered during the study (data not shown); in particular, there were no differences between the values recorded in each individual after treatment compared with baseline values, and no differences between the treatment groups. | medium |
|  | No treatment (aside from CVD drug) | 56 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:10  Median:  SD:  4%  P:  <0.05 |
| Bordia 19989 parallel | At high risk for CHD | Nitrates | NR | Garlic. | 30 |  | Mean: 49.5  Median  SD:  SE:1.6  Lower:  Upper: | Mean:9  % mean22.3:  Median:  SD:  P:  <0.05 | Mean:  Median:  SD:  P: |  | high |
|  | Placebo | 30 | Mean:41.1  Median  SD:  SE:2.8  Lower:  Upper: | Mean:0.1  Median:  SD:  P: |
| Davidson 199715 parallel | Unclear | Simvastatinstatin | 10 | Fish/marine oils | 9 |  | Mean: 44.8  Median  SD:  SE:3.5  Lower:  Upper: | Mean:4.5  % mean: 10.4  Median:  SD:  P:  <0.05 | Mean:  Median:  SD:  P: |  | Medium |
|  | No treatment (aside from CVD drug) | 10 | Mean:45.1  Median  SD:  SE:2.9  Lower:  Upper: | Mean:2.7  % mean 7.2  Median:  SD:  P:  <0.05 |
| Yamamoto 199569 parallel | At high risk for CHD | diltiazem | 90-120 | Omega-3 (EPA, DHA, or both). | 12 |  | Mean: 45  Median  SD:  SE:9  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | No treatment (aside from CVD drug) | 10 | Mean:47  Median  SD:  SE:12  Lower:  Upper: | Mean:  Median:  SD:  P: |
| McDowell 199444  parallel | Unclear | Simvastatinstatin | 20 | Vitamin E. | 8 |  | Mean: 1.3  Median  SD: 0.3  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 8 | Mean:1.3  Median  SD: 0.4  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Kaul 199234  parallel | At high risk for CHD | Calcium channel blocker, ASA | ASA: 150; heparin: 1000 U/d; ca blockers: NR | Fish/marine oils. | 58 |  | Mean: 37  Median  SD: 10.5  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | low-medium |
|  | No treatment (aside from CVD drug) | 49 | Mean:37  Median  SD: 10.5  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Nordøy 200355 parallel | Mod and high risk | atorvastatin | 10 | Fish/marine oils. | 22 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:0.07  % mean:  Median:  SD:  0.08  P: | Mean:  Median:  SD:  P:  0.03 |  | medium |
|  | Placebo | 20 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:0.01  Median:  SD:  0.09  P: |
| Roth 200960  parallel | Unclear | fenofibrates by 100% | 130 | Omega-3 (EPA, DHA, or both). | 81 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median :  -1.9  SD:  P: | Mean:  Median:  SD:  P: | Not significant between groups | medium |
|  | Placebo | 82 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Isley 200731 parallel | Unclear | niacin | 325 | Omega-3 | 7 |  | Mean: 49  Median  SD: 5  SE:  Lower:  Upper: | Mean:  % mean:33  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 8 | Mean:48  Median  SD: 14  SE:  Lower:  Upper: | Mean:  % mean: 18  Median:  SD:  P: |
| Budoff 200410 parallel | At high risk for CHD | statins + aspirin | 10-40 | Garlic | 9 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:3  % mean:  Median:  SD:  10.6  P: | Mean:  Median:  SD:  P:  0.4611 |  | medium |
|  | Placebo | 10 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:-1.3  Median:  SD:  13.8  P: |
| Chan 200212 parallel | At moderate/moderately high risk for CHD (2+ risk factors) | atorvastatin | 40 | Fish/marine oils. | 11 |  | Mean: 1.25  Median  SD:  SE:0.09  Lower:  Upper: | Mean:  % mean: 13.5  Median:  SD:  3.80%  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 13 | Mean: 1.04  Median  SD:  SE: 0.05  Lower:  Upper: | Mean:  % mean:4.5  Median:  SD:  P: |
| Liu 200337  parallel | Unclear | simvastatinstatin | 10 | Fish/marine oils. | 19 |  | Mean: 1.53  Median  SD: 0.36  SE:  Lower:  Upper: | Mean:0.11  % mean:  Median:  SD:  0.21  P: | Mean:  Median:  SD:  P: |  | medium |
|  | No treatment (aside from CVD drug) | 18 | Mean:1.77  Median  SD: 0.54  SE:  Lower:  Upper:7.1 | Mean:0.12  Median:  SD:  0.2  P: |
| Dehmer 198817 parallel | At high risk for CHD | aspirin + Dipyridamole + ca channel blockers) | ASA: 325; dipyridamole: 225; Ca blocker: NR | Omega-3 (EPA, DHA, or both). | 43 |  | Mean: 36  Median  SD: 8.7  SE:  Lower:  Upper: | Mean:  % mean:7.4  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | No treatment (aside from CVD drug) | 39 | Mean:36  Median  SD: 9.4  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Desideri 200318 parallel | At low risk for CHD (0-1 risk factors) | Simvastatinstatin, Bezafibrate | simvastatinstatin: 40; Bezafibrate: 800 | Vitamin E. |  |  | Mean: 1.2  Median  SD: 0.4  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | I assumed no losses to follow-up although I did not see this explicitely stated | medium |
|  | No treatment (aside from CVD drug) |  | Mean:1.1  Median  SD: 0.1  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba |  |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | Study states that: Laboratory findings in all subjects were un-remarkable and did not indicate any differences between the treatment groups. | low-medium |
|  |  |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| De Caterina 200216 crossover | At high risk for CHD | simvastatinstatin | 10-40 | Vitamin E |  |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | Values are presented in graphs, but difficult to read. Statement that "Neither LDL cholesterol nor triglycerides were affected by Vitamin E." | high |
|  | No treatment (aside from CVD drug) |  | Mean:54  Median  SD: 15.3  SE:  Lower:  Upper: | Mean:2.2  Median:  SD:  P: |
| Balestrieri 19964 crossover | Low and/or Moderate | Simvastatinstatin | 10-40 | Fish/marine oils | 14 |  | Mean: 53  Median  SD: 21  SE:  Lower:  Upper: | Mean:2  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 14 | Mean:52  Median  SD: 18  SE:  Lower:  Upper: | Mean:2  Median:  SD:  P: |
| Paolisso 199556 crossover | At high risk for CHD | nifedipine | 88 | Vitamin E | 30 |  | Mean: 0.89  Median  SD:  SE:0.04  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P:  <0.05 |  | medium |
|  | Placebo | 30 | Mean:0.78  Median  SD: 0.07  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Hansen199329 crossover | Low and/or Moderate | lovastatin | 40 | Fish/marine oils | 14 |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean: 6  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 14 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:14  Median:  SD:  P: |
| Mueller 199151 crossover | Low and/or Moderate | aspirin | 325-single dose | Fish/marine oils | 12 |  | Mean: 46.17  Median  SD: 11.56  SE:  Lower:  Upper: | Mean:3.34  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 12 | Mean:44.25  Median  SD: 9.17  SE:  Lower:  Upper: | Mean:1.42  Median:  SD:  P: |
| Maki 200841 crossover | Low and/or Moderate | simvastatin | 20 | Omega-3 | 39 |  | Mean:  Median 45  SD:  SE:  Lower: 27  Upper:106 | Mean:  % mean:  Median: 16.4%  SD:  P: | Mean:  Median: 7.2  SD:  P:  0.001 | The IQRs reported are actually ranges (low-high). | medium |
|  | Placebo | 39 | Mean:  Median 41  SD:  SE:  Lower: 29  Upper:93 | Mean:  Median:10.6%  SD:  P: |